Delivery Order SPE2DB24D1007-SPE2DB24FBZVY

Award Date 7/9/24
Potential Completion Date 7/10/24
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $47,865.60 firm-fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $13,072.56 Firm Fixed Price Delivery Order contract is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of March 12, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,228.50 firm fixed-price delivery order is for the provision of ELIQUIS 2.5 MG TABLET 60S, a cardiovascular medication. The contract has an ultimate completion date of January 9, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,133.72 firm fixed-price delivery order is for the supply of ELIQUIS 2.5 mg tablets, a pharmaceutical product used for various medical treatments. The contract has an ultimate completion date of March 4, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $1,900.08 to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical company Amerisourcebergen Corporation. This order is for the supply of ELIQUIS 2.5 mg tablets and is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,554.20 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of May 28, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,656.68 firm fixed-price delivery order is for the supply of 4,563,894,799 units of the medication ELIQUIS 5 MG TABLET 60S. The contract has an ultimate completion date of March 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,115.92 Firm Fixed Price delivery order is for ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This federal contract award is a delivery order placed by the Defense Logistics Agency (DLA) Troop Support Medical with Amerisourcebergen Drug Corp's Corporate Office Division. The $1,424.70 firm fixed-price contract is for the supply of ELIQUIS 2.5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of August 2, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this delivery order as part of its broader Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,965.60 firm fixed-price delivery order is for the supply of ELIQUIS 2.5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 7, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB24D1007
    Indefinite Delivery Contract
  • SPE2DB24D1007-SPE2DB24FBZVY
    Delivery Order

This federal contract award is for a Delivery Order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, to provide ELIQUIS 2.5 MG TABLET 60S. The contract has a firm fixed price ceiling value of $1,900.08 and an ultimate completion date of July 10, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This specific Delivery Order did not utilize a set-aside designation.

Generated 10/8/24, 9:11 AM